{"entity":{"id":"mk-1045","kind":"drug","name":"MK-1045","aka":[],"tldr":"MK-1045 is an experimental investigational agent whose form is not stated in the registry from Merck Sharp & Dohme in phase 3 trials for acute lymphoblastic leukaemia, follicular lymphoma and hodgkin lymphoma, aimed at CD19.","summary":"MK-1045 (CN-201, CN201) is an investigational agent whose form is not stated in the registry developed by Merck Sharp & Dohme and MSD R&D (China). Its target is CD19 (the sponsor names CD19). The sponsor states: MK-1045 is described as a novel immunotherapy, given intravenously, being compared with blinatumomab in relapsed/refractory CD19-positive B-cell acute lymphoblastic leukaemia. It is the investigational product in 4 recruiting or active industry-led phase 2 and phase 3 interventional cancer trials, including phase 3 studies NCT07570173 (A Clinical Trial of MK-1045 in People With B-cell Acute Lymphoblastic Leukaemia (MK-1045-005)) and NCT07634471 (A Clinical Trial of MK-1045 and Rituximab in People With Follicular Lymphoma (MK-1045-007)), in acute lymphoblastic leukaemia, follicular lymphoma, hodgkin lymphoma and diffuse large B-cell lymphoma. The largest, NCT07634471, plans to enrol 960 participants with primary completion expected 2032-07-23. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.","status":"phase-3","asOf":"2026-09-11","links":[{"label":"ClinicalTrials.gov: trials of MK-1045","url":"https://clinicaltrials.gov/search?intr=CN-201"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["all-leukemia","follicular-lymphoma","hodgkin-lymphoma","dlbcl"],"sections":[],"technologies":[],"targets":["cd19"],"drugs":[],"companies":["merck"],"institutions":[],"pathways":[],"terms":[],"trials":["nct07570173","nct07634471","nct07519772","nct05579132"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor pipeline pages)","editedOn":"2026-09-11"},"code":"CN-201, CN201","modality":"bispecific antibody (CD3 x CD19, per the sponsor's description; form not stated in the registry record)","mechanism":"MK-1045 is described as a novel immunotherapy, given intravenously, being compared with blinatumomab in relapsed/refractory CD19-positive B-cell acute lymphoblastic leukaemia.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/mk-1045/","neighbours":{"cancer":[{"id":"all-leukemia","kind":"cancer","name":"Acute lymphoblastic leukaemia","route":"/cancers/all-leukemia/"},{"id":"dlbcl","kind":"cancer","name":"Diffuse large B-cell lymphoma","route":"/cancers/dlbcl/"},{"id":"follicular-lymphoma","kind":"cancer","name":"Follicular lymphoma","route":"/cancers/follicular-lymphoma/"},{"id":"hodgkin-lymphoma","kind":"cancer","name":"Hodgkin lymphoma","route":"/cancers/hodgkin-lymphoma/"}],"target":[{"id":"cd19","kind":"target","name":"CD19","route":"/targets/cd19/"}],"company":[{"id":"merck","kind":"company","name":"Merck & Co. (MSD)","route":"/companies/merck/"}],"trial":[{"id":"nct05579132","kind":"trial","name":"A Clinical Study of MK-1045 (CN201) in People With Precursor B-cell Acute Lymphoblastic Leukemia (MK-1045-002)","route":"/trials/nct05579132/"},{"id":"nct07519772","kind":"trial","name":"A Clinical Study of MK-1045 in People With Non-Hodgkin Lymphoma (MK-1045-008)","route":"/trials/nct07519772/"},{"id":"nct07634471","kind":"trial","name":"A Clinical Trial of MK-1045 and Rituximab in People With Follicular Lymphoma (MK-1045-007)","route":"/trials/nct07634471/"},{"id":"nct07570173","kind":"trial","name":"A Clinical Trial of MK-1045 in People With B-cell Acute Lymphoblastic Leukemia (MK-1045-005)","route":"/trials/nct07570173/"}]}}